On June 18, Sanofi fell 3.11% in regular trading, trading at $42.68/share, with turnover of $290 million. The decline reflects ongoing market pressure following the company's announcement on June 10 that it would terminate its Phase III MOBILIZE trial for core pipeline drug riliprubart in refractory chronic inflammatory demyelinating polyneuropathy (CIDP).

The decision was based on an independent data monitoring committee's interim analysis, which concluded the study was unlikely to achieve its pre-specified efficacy endpoint. No safety signals were identified. Riliprubart, an IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway, had been considered a key pipeline asset. The company indicated that other riliprubart studies, including the Phase III VITALIZE trial, would be reassessed accordingly.

The trial failure disrupts Sanofi's strategy of building a robust new product pipeline to offset the approaching patent cliff for its blockbuster drug Dupixent. Multiple research setbacks — including mixed data for eczema drug amlitelimab and delayed U.S. approval of tolebrutinib — have compounded investor concerns, with institutional buy ratings declining to 43% in recent months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)